Bradmer Pharmaceuticals Inc. (TSE:GLX – Free Report) – Atb Cap Markets lowered their FY2024 earnings estimates for shares of Bradmer Pharmaceuticals in a note issued to investors on Sunday, January 26th. Atb Cap Markets analyst M. Toner now anticipates that the company will post earnings per share of $3.01 for the year, down from their previous estimate of $3.63. Atb Cap Markets also issued estimates for Bradmer Pharmaceuticals’ FY2025 earnings at $1.51 EPS.
Separately, HC Wainwright upgraded shares of Bradmer Pharmaceuticals to a “strong-buy” rating in a report on Thursday, October 10th.
Bradmer Pharmaceuticals Price Performance
Bradmer Pharmaceuticals (TSE:GLX – Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The company reported C($0.18) EPS for the quarter, topping analysts’ consensus estimates of C($0.52) by C$0.34.
See Also
- Five stocks we like better than Bradmer Pharmaceuticals
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- How to Invest in Insurance Companies: A Guide
- 3 Steel Stocks Soaring After Tariff Announcements
- NYSE Stocks Give Investors a Variety of Quality Options
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
